Obesity, serious mental illness and antipsychotic drugs
- 28 May 2009
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 11 (7), 665-679
- https://doi.org/10.1111/j.1463-1326.2009.01038.x
Abstract
The prevalence of overweight and obesity is higher in people with mental illness than in the general population. Body weight is tightly regulated by a complex system involving the cortex and limbic system, the hypothalamus and the gastrointestinal tract. While there are justifiable concerns about the weight gain associated with antipsychotic medication, it is too simplistic to ascribe all obesity in people with serious mental illness (SMI) to their drug treatment. The development of obesity in SMI results from the complex interaction of the genotype and environment of the person with mental illness, the mental illness itself and antipsychotic medication. There are dysfunctional reward mechanisms in SMI that may contribute to poor food choices and overeating. While it is clear that antipsychotics have profound effects to stimulate appetite, no one receptor interaction provides an adequate explanation for this effect, and many mechanisms are likely to be involved. The complexity of the system regulating body weight allows us to start to understand why some individuals appear much more prone to weight gain and obesity than others.This publication has 100 references indexed in Scilit:
- Common variants near MC4R are associated with fat mass, weight and risk of obesityNature Genetics, 2008
- Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weightPhysiology & Behavior, 2007
- Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disordersJournal of Neural Transmission, 2007
- Antipsychotic drug-induced weight gain mediated by histamine H1receptor-linked activation of hypothalamic AMP-kinaseProceedings of the National Academy of Sciences of the United States of America, 2007
- Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medicationJournal of the American Dietetic Association, 2005
- Is cannabis an anti-antipsychotic? The experience in psychiatric intensive careHuman Psychopharmacology: Clinical and Experimental, 2005
- Recent advances in the genetics of schizophreniaHuman Molecular Genetics, 2003
- Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compoundsLife Sciences, 2000
- The Effects of Treatment with Recombinant Human Growth Hormone on Body Composition and Metabolism in Adults with Growth Hormone DeficiencyThe New England Journal of Medicine, 1989
- Weight Changes With Schizophrenic Psychosis and Psychotropic Drug TherapyPsychosomatics, 1970